Bandari Bharathwaj Chetty

Mr. Bandari Bharathwaj Chetty

Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in ACS Omega
Verified
Journal Article
Open access
MHMangala Hegde
Mangala Hegde
SGSosmitha Girisa
Sosmitha Girisa
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
RVRavichandran Vishwa
Ravichandran Vishwa
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Curcumin has been credited with a wide spectrum of pharmacological properties for the prevention and treatment of several chronic diseases such as arthritis, autoimmune diseases, cancer, cardiovascular diseases, diabetes, hemoglobinopathies, hypertension, infectious diseases, inflammation, metabolic syndrome, neurological diseases, obesity, and skin diseases. However, due to its weak solubility and bioavailability, it has limited potential as an oral medication. Numerous factors including low water solubility, poor intestinal permeability, instability at alkaline pH, and fast metabolism contribute to curcumin's limited oral bioavailability. In order to improve its oral bioavailability, different formulation techniques such as coadministration with piperine, incorporation into micelles, micro/nanoemulsions, nanoparticles, liposomes, solid dispersions, spray drying, and noncovalent complex formation with galactomannosides have been investigated with in vitro cell culture models, in vivo animal models, and humans. In the current study, we extensively reviewed clinical trials on various generations of curcumin formulations and their safety and efficacy in the treatment of many diseases. We also summarized the dose, duration, and mechanism of action of these formulations. We have also critically reviewed the advantages and limitations of each of these formulations compared to various placebo and/or available standard care therapies for these ailments. The highlighted integrative concept embodied in the development of next-generation formulations helps to minimize bioavailability and safety issues with least or no adverse side effects and the provisional new dimensions presented in this direction may add value in the prevention and cure of complex chronic diseases.

Verified
Journal Article
Open access
PDF file
SJSujitha Jayaprakash
Sujitha Jayaprakash
MHMangala Hegde
Mangala Hegde
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
SGSosmitha Girisa
Sosmitha Girisa
MAMohammed Alqahtani
Mohammed Alqahtani
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Cancer is a deadly disease worldwide, with an anticipated 19.3 million new cases and 10.0 million deaths occurring in 2020 according to GLOBOCAN 2020. It is well established that carcinogenesis and cancer development are strongly linked to genetic changes and post-translational modifications (PTMs). An important PTM process, ubiquitination, regulates every aspect of cellular activity, and the crucial enzymes in the ubiquitination process are E3 ubiquitin ligases (E3s) that affect substrate specificity and must therefore be carefully regulated. A surfeit of studies suggests that, among the E3 ubiquitin ligases, neuronal precursor cell-expressed developmentally downregulated 4 (NEDD4)/NEDD4-like E3 ligases show key functions in cellular processes by controlling subsequent protein degradation and substrate ubiquitination. In addition, it was demonstrated that NEDD4 mainly acts as an oncogene in various cancers, but also plays a tumor-suppressive role in some cancers. In this review, to comprehend the proper function of NEDD4 in cancer development, we summarize its function, both its tumor-suppressive and oncogenic role, in multiple types of malignancies. Moreover, we briefly explain the role of NEDD4 in carcinogenesis and progression, including cell survival, cell proliferation, autophagy, cell migration, invasion, metastasis, epithelial-mesenchymal transition (EMT), chemoresistance, and multiple signaling pathways. In addition, we briefly explain the significance of NEDD4 as a possible target for cancer treatment. Therefore, we conclude that targeting NEDD4 as a therapeutic method for treating human tumors could be a practical possibility.

22 March 2024 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
ASAnjana Sajeev
Anjana Sajeev
RVRavichandran Vishwa
Ravichandran Vishwa
AAAswani Babu Santha Aswani
Aswani Babu Santha Aswani
MAMohammed Alqahtani
Mohammed Alqahtani
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara

9 February 2024 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
MKM MUKESH KUMAR
M MUKESH KUMAR
ASAnjana Sajeev
Anjana Sajeev
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
MAMohammed Alqahtani
Mohammed Alqahtani
MAMohamed Abbas
Mohamed Abbas
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Hematological malignancies (HM) represent a subset of neoplasms affecting the blood, bone marrow, and lymphatic systems, categorized primarily into leukemia, lymphoma, and multiple myeloma. Their prognosis varies considerably, with a frequent risk of relapse despite ongoing treatments. While contemporary therapeutic strategies have extended overall patient survival, they do not offer cures for advanced stages and often lead to challenges such as acquisition of drug resistance, recurrence, and severe side effects. The need for innovative therapeutic targets is vital to elevate both survival rates and patients' quality of life. Recent research has pivoted towards nuclear receptors (NRs) due to their role in modulating tumor cell characteristics including uncontrolled proliferation, differentiation, apoptosis evasion, invasion and migration. Existing evidence emphasizes NRs' critical role in HM. The regulation of NR expression through agonists, antagonists, or selective modulators, contingent upon their levels, offers promising clinical implications in HM management. Moreover, several anticancer agents targeting NRs have been approved by the Food and Drug Administration (FDA). This review highlights the integral function of NRs in HM's pathophysiology and the potential benefits of therapeutically targeting these receptors, suggesting a prospective avenue for more efficient therapeutic interventions against HM. Graphical abstract

6 January 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
BABabu Santha Aswani
Babu Santha Aswani
SSShweta S. Shinde
Shweta S. Shinde
MAMohammed S. Alqahtani
Mohammed S. Alqahtani
MAMohamed Abbas
Mohamed Abbas
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
The nuclear factor kappa B (NF-κB) signalling pathway is a pivotal orchestrator of inflammation, tumour progression, immune modulation, and metabolic

17 October 2023 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
ASAnjana Sajeev
Anjana Sajeev
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
RVRavichandran Vishwa
Ravichandran Vishwa
MAMohammed Alqahtani
Mohammed Alqahtani
MAMohamed Abbas
Mohamed Abbas
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Head and neck cancers (HNC) encompass a broad spectrum of neoplastic disorders characterized by significant morbidity and mortality. While contemporary therapeutic interventions offer promise, challenges persist due to tumor recurrence and metastasis. Central to HNC pathogenesis is the aberration in numerous signaling cascades. Prominently, the Wnt signaling pathway has been critically implicated in the etiology of HNC, as supported by a plethora of research. Equally important, variations in the expression of non-coding RNAs (ncRNAs) have been identified to modulate key cancer phenotypes such as cellular proliferation, epithelial-mesenchymal transition, metastatic potential, recurrence, and treatment resistance. This review aims to provide an exhaustive insight into the multifaceted influence of ncRNAs on HNC, with specific emphasis on their interactions with the Wnt/β-catenin (WBC) signaling axis. We further delineate the effect of ncRNAs in either exacerbating or attenuating HNC progression via interference with WBC signaling. An overview of the mechanisms underlying the interplay between ncRNAs and WBC signaling is also presented. In addition, we described the potential of various ncRNAs in enhancing the efficacy of chemotherapeutic and radiotherapeutic modalities. In summary, this assessment posits the potential of ncRNAs as therapeutic agents targeting the WBC signaling pathway in HNC management.